VRTX · 10-Q · 2026Q2 · Full report
Crinetics Acquisition Financing
VERTEX PHARMACEUTICALS INC / MA · 2026-08-04 · Importance 71 · Surprise 60 · In source text
In July 2026, Vertex agreed to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, representing approximately $10.0 billion of equity value. Crinetics contributes FDA- and EMA-approved PALSONIFY for acromegaly and the Phase 3 atumelnant program for congenital adrenal hyperplasia. Vertex expects the transaction to close in the third quarter of 2026, subject to customary conditions, and will account for it when it closes. Funding will come from cash, cash equivalents, and proceeds from a newly established $4.5 billion 2026 Term Loan, with the acquisition not conditioned on financing.
Key facts
- Plan to fund the Crinetics acquisition with cash, cash equivalents, and proceeds from the 2026 Term Loan; the acquisition is not conditioned on receipt of financing source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | probable | — | Plan to fund the Crinetics acquisition with cash, cash equivalents, and proceeds from the 2026 Term Loan; the acquisition is not… |